Trial
NCT03433755
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
—
Condition
Primary Hypercholesterolemia
Intervention
evolocumab
Why stopped
Prematurely Discontinued Amgen decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-27